Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 1.62 | 1.64 | 0.02 |
Stocks | 95.84 | 95.84 | 0.00 |
Other | 2.53 | 2.70 | 0.17 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 13.80 | 14.05 |
Price to Book | 2.21 | 2.07 |
Price to Sales | 0.98 | 1.26 |
Price to Cash Flow | 7.13 | 9.11 |
Dividend Yield | 2.85 | 3.04 |
5 Years Earnings Growth | 6.62 | 9.71 |
Name | Net % | Category Average |
---|---|---|
Industrials | 29.02 | 20.66 |
Healthcare | 15.11 | 9.96 |
Consumer Cyclical | 13.18 | 13.36 |
Financial Services | 12.11 | 16.61 |
Energy | 9.92 | 6.95 |
Consumer Defensive | 9.79 | 11.25 |
Communication Services | 6.18 | 6.71 |
Utilities | 2.78 | 4.03 |
Basic Materials | 1.91 | 5.88 |
Number of long holdings: 52
Number of short holdings: 6
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Shell | GB00BP6MXD84 | 7.74 | 31.14 | +0.94% | |
Compass | GB00BD6K4575 | 4.57 | 2,401.00 | -0.54% | |
Unilever | GB00B10RZP78 | 4.14 | 57.18 | +0.07% | |
HALEON | GB00BMX86B70 | 3.85 | 386.60 | -0.39% | |
Rentokil | GB00B082RF11 | 3.74 | 364.20 | +0.61% | |
GSK plc | GB00BN7SWP63 | 3.61 | 1,459.50 | -0.07% | |
NatWest Group | GB00BM8PJY71 | 3.30 | 342.50 | +3.88% | |
AstraZeneca | GB0009895292 | 3.22 | 11,738.0 | -1.89% | |
Ashtead Group | GB0000536739 | 3.11 | 5,612.0 | -0.28% | |
Relx | GB00B2B0DG97 | 2.87 | 3,501.00 | -1.41% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Majedie UK Equity Fund Class B Inc | 6.48M | 15.33 | 6.25 | 5.99 | ||
Majedie UK Focus Class X Accumulati | 6.51M | 14.83 | 2.51 | 5.71 | ||
Majedie UK Focus Class X Income | 3.91M | 14.82 | 2.51 | 5.72 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review